Oramed Pharmaceuticals Inc. (ORMP) AI Stock Analysis

Oramed Pharmaceuticals Inc., headquartered in New York, focuses on developing oral delivery methods for pharmaceutical treatments, primarily targeting diabetes and liver disorders. Founded in 2002, the company designs ingestible capsules and pills that deliver polypeptides. Its lead product candidate is ORMD-0801 Type 2, an oral insulin capsule that has finished phase II clinical trials for individuals with diabetes. In addition, the company is evaluating ORMD-0801 in phase 2 clinical trials for non-alcoholic steatohepatitis (NASH). Oramed is also advancing ORMD-0901, an oral GLP-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes.

Oramed's financial results reflect its clinical-stage profile, with a 5-year revenue CAGR of -5.8% from FY2019 to FY2025. Annual revenue shifted from $2.7M in FY2020, FY2021, and FY2022 to $1.3M in FY2023, before rising 49.3% to $2.0M in FY2025. Operating margins remained deeply negative across those periods, registering -754.4% in FY2025. Net income was -$11.5M in FY2020, -$22.2M in FY2021, and -$37.8M in FY2022, before turning positive to $5.5M in FY2023 and $64.0M in FY2025. For the trailing twelve months ended June 30, 2026, revenue stood at $0 with quarterly revenue down 100.0% year-over-year, while quarterly earnings grew 493.5% and EPS reached $4.13.

As of June 30, 2026, Oramed held $50.6M in cash and short-term investments against total debt of $733,000, resulting in net cash of $49.9M. Total assets were $369.6M, shareholders' equity was $317.5M, and the current ratio stood at 4.98 with a debt-to-equity ratio of 0.00. The company generates negative cash flows from operations, including -$9.1M in operating cash flow and -$11.1M in free cash flow in FY2025. Capital allocation in FY2025 included $1.9M in capital expenditures, $4.7M in share buybacks, and $10.9M in dividends paid.

At $4.07, Oramed has a market capitalization of $169.3M and an enterprise value of $146.5M. The stock trades at a trailing P/E of 1.0x and an EV/EBITDA of 1.9x, compared to medians of 24.6x and 12.0x, respectively, for US-listed Healthcare peers. Its price-to-sales ratio is 86.6x compared to 4.1x for its peer group, and price-to-book is 0.6x. Over the past year, ORMP returned 92.3%, outpacing the S&P 500's 16.8% return, but its 5-year return of -80.2% lags the index's 83.0% gain.

Oramed carries a forward annual dividend of $0.25, representing a dividend yield of 6.13% and a payout ratio of 11.3%. In FY2025, the company paid $10.9M in dividends. Its last ex-dividend date was January 16, 2026.

Analysts have a mean price target of $7.00 for Oramed, representing a 72.0% premium over its last closing price of $4.07. For the fiscal year ending December 31, 2026, consensus estimates project EPS of $4.47, reflecting 198.0% growth, alongside $0 in revenue. Revenue for the next fiscal year is also estimated at $0. Over the last four quarters, Oramed exceeded EPS estimates 3 times. The next earnings release date is November 12, 2026.

This page is an AI-written research summary of Oramed Pharmaceuticals Inc. (ORMP). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ORMP income statement, ORMP balance sheet, ORMP key metrics, ORMP analyst forecast, ORMP chart. See the ORMP stock overview for the latest quote and news.